Sickle Cell Disease Clinical Trials in Philadelphia, Pennsylvania

10 studies are recruiting for sickle cell disease in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

   This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can red…

   Stage

   Phase 3

   Ages

   12 and older

   Site

   Children's Hosptl Philadelphia, Philadelphia, Pennsylvania

   Locations

   175 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT06612268 on ClinicalTrials.gov

2. A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

   A phase III, multi-center, randomized, placebo-controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult Sickle Cell Disease patients with frequent vaso-occlusive crises.

   Stage

   Phase 3

   Ages

   12 to 100

   Site

   Thomas Jefferson University Me, Philadelphia, Pennsylvania

   Locations

   35 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06439082 on ClinicalTrials.gov

3. A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary food effect of ITU512 as well as the fetal hemoglobin (HbF)-inducing capacity of ITU512. This will be the first evaluation of the potential therapeutic effect of ITU512 in healthy participants …

   Stage

   Phase 1

   Ages

   12 to 55

   Site

   Childrens Hospital Of Philadelphia, Philadelphia, Pennsylvania

   Locations

   10 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06546670 on ClinicalTrials.gov

4. ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

   In parallel with the growth of ATHN's clinical studies, the number of new therapies for all blood disorders is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have not yet demonstrated long-term safety and effectiveness beyond…

   Stage

   Not phased

   Ages

   Any age

   Site

   Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

   Locations

   76 in total

   Run by

   American Thrombosis and Hemostasis Network

   See if you can join NCT04398628 on ClinicalTrials.gov

5. Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

   This is a multi-center multi-national rollover study to allow continued access to crizanlizumab for patients with sickle cell disease (SCD) who are on crizanlizumab treatment in a Novartis-sponsored study (parent study) and are benefiting from the treatment as judged by the investigator.

   Stage

   Phase 4

   Ages

   0 to 100

   Site

   Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania

   Locations

   31 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT04657822 on ClinicalTrials.gov

6. Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease

   This trial will determine whether adding ruxolitinib to a reduced intensity conditioning (RIC) regimen reduces the rate of graft failure following haploidentical (haplo) hematopoietic cell transplant (HCT) for children and young adults with sickle cell disease (SCD). This study will enroll and trea…

   Stage

   Phase 1

   Ages

   12 to 45

   Site

   Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

   Locations

   4 in total

   Run by

   Arkansas Children's Hospital Research Institute

   See if you can join NCT07252050 on ClinicalTrials.gov

7. Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial

   The goal of this short term prospective Phase II study is to compare the effects of two alternate daily doses of zinc (25 and 40 mg/day) in 34 randomly assigned homozygous Sickle Cell Disease (SCD-SS) patients aged 15-40 years old. The main question it aims to answer is: Which biomarkers are most r…

   Stage

   Phase 2

   Ages

   15 to 40

   Site

   Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

   Locations

   6 in total

   Run by

   University of California, San Francisco

   See if you can join NCT06260891 on ClinicalTrials.gov

8. Stress Management and Mindfulness Intervention for Patients With Sickle Cell Disease

   The purpose of this research is to determine whether a new stress management and mindfulness program can improve quality of life in individuals with sickle cell disease. The program is based on a number of empirically supported treatments including techniques from cognitive-behavioral therapy like …

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Run by

   University of Pennsylvania

   See if you can join NCT07316478 on ClinicalTrials.gov

9. A Long-term Follow-up Study in Patients Who Received BEAM-101

   This is a Long-term Follow-up (LTFU) study in patients who received BEAM-101 in the parent study (Study BTX-AUT-001). Eligible patients who received BEAM-101 will be asked to participate in this LTFU study prior to completing Study BTX-AUT-001. Patients who enter into this study will be followed fo…

   Stage

   Not phased

   Ages

   14 to 37

   Site

   Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

   Locations

   17 in total

   Run by

   Beam Therapeutics Inc.

   See if you can join NCT07373639 on ClinicalTrials.gov

10. Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease

    The goal of this observational study is to help us understand more about the best ways to help individuals living with Sickle Cell Disease (SCD) get the best care. The main question it aims to answer is: How to find individuals unaffiliated from SCD specialist care use three distinct pathways? Once…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Pennsylvania, Philadelphia, Pennsylvania

    Locations

    9 in total

    Run by

    RTI International

    See if you can join NCT06385886 on ClinicalTrials.gov